Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Trial details
- Registry ID
- NCT04802837
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsNCT04802837 | Summit Therapeutics | Phase 3 | Terminated | 2021-09-17Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |